Antigenics Inc. (Lexington, MA)'s QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline’s Malaria Vaccine

LEXINGTON, Mass.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that GlaxoSmithKline (GSK) has launched a Phase 3 study with the world’s most clinically-advanced malaria vaccine, RTS,S, which contains Antigenics’ QS-21 Stimulon® adjuvant.